UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 22nd September
2020, London, UK and Paris, France
Sanofi and
GSK sign agreements with the
Government of Canada to supply up to 72 million doses of adjuvanted
COVID-19 vaccine
● Agreements relate to vaccine candidate using
Sanofi's recombinant protein-based technology and GSK's pandemic
adjuvant
● Both companies are committed to making their
COVID-19 vaccine affordable and available
globally
Sanofi and GSK have today signed agreements with the Government of
Canada for the supply of up to 72 million doses of an adjuvanted
COVID-19 vaccine, beginning in 2021.
Thomas Triomphe, Executive Vice President and Global Head of Sanofi
Pasteur, said:
"Today's announcement showcases our unwavering commitment to
develop a COVID-19 vaccine that is available to everyone when it
comes to market. To address a global health crisis of this
magnitude, it takes partnerships and we are grateful to Canada for
their collaboration, and to GSK for partnering with us to develop a
safe and effective vaccine."
Roger Connor, President of GSK Vaccines said:
"GSK is proud to be working in partnership with Sanofi to make this
vaccine available as soon as possible in Canada. Both companies
have significant R&D and manufacturing capability world-wide
and are already working hard to scale up production. This
announcement from the Government of Canada supports our ongoing
efforts."
Both companies have vaccine manufacturing sites in Canada that are
contributing to overall global COVID-19 vaccine development, and
these plus their global industrial networks will play a pivotal
role in the production of the COVID-19 vaccine doses for Canada -
as agreed today.
The Companies initiated a Phase 1/ 2 study on 3rd September
and anticipate first results in early December 2020, to support the
initiation of a Phase 3 study before the end of the year. If
these data are sufficient for licensure application, it is planned
to request regulatory approval in the first half of 2021. In
parallel, Sanofi and GSK are scaling up manufacturing of the
antigen and adjuvant with the target of producing up to one billion
doses in total per year globally.
Sanofi and GSK are committed to making the COVID-19 vaccine
available globally
On 18th September
Sanofi and GSK signed a final agreement with the European
Commission to supply European countries with up to 300 million
doses from their European industrial networks.
In July 2020, Sanofi and GSK announced a collaborative
effort with the U.S. government to supply up to 100 million doses
of their adjuvanted COVID-19 recombinant vaccine. The U.S.
government has a further option to discuss the purchase of up to an
additional 500 million doses longer term. Both Companies
also agreed with
the UK government to supply up to 60 million doses of recombinant
protein-based COVID-19 vaccine.
The partners plan to supply a significant portion of total
worldwide available supply to COVAX, the vaccines pillar of the
ACT-Accelerator (Access to COVID‐19
Tools), a global collaboration of leaders of governments, global
health organizations, businesses and philanthropies to accelerate
development, production, and equitable access to COVID-19 tests,
treatments, and vaccines.
GSK commitment to tackling COVID-19
GSK is collaborating with companies and research groups across the
world working on promising COVID-19 vaccine candidates through the
use of our pandemic adjuvant technology. The use of an adjuvant is
of particular importance in a pandemic situation since it may
reduce the amount of vaccine protein required per dose, allowing
more vaccine doses to be produced and therefore contributing to
protecting more people. GSK does not expect to profit from
COVID-19 vaccines during the pandemic phase, and will invest any
short-term profit in coronavirus related research and long-term
pandemic preparedness, either through GSK internal investments or
with external partners.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
GSK enquiries:
|
|
|
|
Media
enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
Kristen
Neese
|
+1 804
217 8147
|
(Philadelphia)
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
Danielle
Smith
|
+44 (0)
20 8047 0932
|
(London)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking
statements or projections made by GSK, including those made in this
announcement, are subject to risks and uncertainties that may cause
actual results to differ materially from those projected. Such
factors include, but are not limited to, those described under Item
3.D "Risk Factors" in the company's Annual Report on Form 20-F for
2019 and as set out in GSK's Principal risks and uncertainties"
section of the Q2 Results and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: September
22, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024